Repatha 140 MG/ML sureclickml
Ended Awarded Last action
- Contract number
- SPE2DR26F03A8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,760
Award facts
- Contract value 100% obligated
- $17,760.26 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $17,760.26 on January 12, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitive award was made by the Defense Logistics Agency, a subordinate agency of the Department of Defense responsible for supplying medical and pharmaceutical products to military healthcare systems. The contract utilizes firm fixed pricing and is expected to be completed by January 13, 2026. The award includes no set-aside designation, indicating open competition among qualified vendors. Amerisourcebergen Drug Corp performs as the child entity of parent company Cencora, Inc., which does business as Amerisourcebergen.
This delivery order is executed under Cencora, Inc.'s significantly larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical, valued at up to $999,999,999.00 through December 2031. This primary contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Repatha, a PCSK9 inhibitor used in cardiovascular disease management, represents one of the specialized pharmaceutical products delivered through this strategic partnership supporting Defense Health Agency and other federal military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F03A8?
SPE2DR26F03A8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 12, 2026.
How much is contract SPE2DR26F03A8 worth?
The government has obligated $17,760 on SPE2DR26F03A8.
Is contract SPE2DR26F03A8 an order under another contract?
Yes. SPE2DR26F03A8 is a delivery order under SPE2DR25D2200, an indefinite delivery contract.
Was contract SPE2DR26F03A8 competed?
The extent of competition for SPE2DR26F03A8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award